ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,571,091 | -22.4% | 128,170 | +9.2% | 0.00% | 0.0% |
| Q2 2023 | $3,311,741 | +168008.7% | 117,396 | +2.5% | 0.00% | 0.0% |
| Q1 2023 | $1,970 | -15.7% | 114,511 | -1.3% | 0.00% | 0.0% |
| Q4 2022 | $2,338 | -99.9% | 116,070 | -6.1% | 0.00% | 0.0% |
| Q3 2022 | $2,677,000 | -15.2% | 123,566 | +10.0% | 0.00% | 0.0% |
| Q2 2022 | $3,157,000 | -45.5% | 112,327 | -5.1% | 0.00% | -50.0% |
| Q1 2022 | $5,792,000 | -32.6% | 118,322 | -1.9% | 0.00% | -33.3% |
| Q4 2021 | $8,599,000 | -5.2% | 120,656 | -6.5% | 0.00% | 0.0% |
| Q3 2021 | $9,069,000 | +24.8% | 129,039 | -5.5% | 0.00% | +50.0% |
| Q2 2021 | $7,267,000 | +43.3% | 136,599 | +16.9% | 0.00% | 0.0% |
| Q1 2021 | $5,072,000 | -7.9% | 116,900 | +10.3% | 0.00% | 0.0% |
| Q4 2020 | $5,505,000 | +314.2% | 105,992 | +160.9% | 0.00% | +100.0% |
| Q3 2020 | $1,329,000 | -31.6% | 40,633 | +0.4% | 0.00% | 0.0% |
| Q2 2020 | $1,943,000 | – | 40,464 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |